USFDA approves Santhera’s New Molecular Entiry Vamorolone (AGAMREE) for DMD Read More

Vamorolone is a synthetic corticosteroid approved by USFDA for the treatment of Duchenne Muscular Dystrophy (DMD). DMD is a rare inherited X-chromosome-linked disease manifested as progressive muscle degeneration and weakness, due to a lack of muscle protein called dystrophin. FDA granted orphan drug designation to Agamree. Santhera has also received positive review for Vamorolone in Europe and expect approval by late 2023.

Announcement